1、 吕磊,谭文亮,吴天源,等.急性冠脉综合征患者基因分型对血小板聚集率影响的研究[J].广州医药,2016,47(5):20-23. 吕磊,谭文亮,吴天源,等.急性冠脉综合征患者基因分型对血小板聚集率影响的研究[J].广州医药,2016,47(5):20-23.
2、 TAN S Y,WAN X A,MICHAEL W,et al.CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events[J].J Clin Pharm Ther,2020,45(1):52-58. TAN S Y,WAN X A,MICHAEL W,et al.CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events[J].J Clin Pharm Ther,2020,45(1):52-58.
3、 KASPAR B,ANNE K A,SINDRE W,et al.Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction[J].JAM Coll Cardiol,2021,77(15):1845-1855. KASPAR B,ANNE K A,SINDRE W,et al.Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction[J].JAM Coll Cardiol,2021,77(15):1845-1855.
4、 ALEXANDER P,KLAUS K,JULIAN M,et al.Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort[J].Clin Res Cardiol,2020,109(3):315-323. ALEXANDER P,KLAUS K,JULIAN M,et al.Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort[J].Clin Res Cardiol,2020,109(3):315-323.
5、 郭元元,王丽英,张宇,等.冠心病患者CYP2C19基因多态性及临床不良事件发生与氯吡格雷抵抗的关系[J].检验医学与临床,2021,18(8):1054-1058. 郭元元,王丽英,张宇,等.冠心病患者CYP2C19基因多态性及临床不良事件发生与氯吡格雷抵抗的关系[J].检验医学与临床,2021,18(8):1054-1058.
6、 RIM C,KHADIJA M,MIRIAM B,et al.Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism[J].Tunis Med,2018,96(3):209-218. RIM C,KHADIJA M,MIRIAM B,et al.Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism[J].Tunis Med,2018,96(3):209-218.
7、 FELIX R,LIZETH M,YADIRA X,et al.Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico[J].Arch Cardiol Mex,2021,89(4):324-329. FELIX R,LIZETH M,YADIRA X,et al.Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico[J].Arch Cardiol Mex,2021,89(4):324-329.
8、 吴天源,李韶南,罗义,等.CYP2C19中代谢型急性冠脉综合征患者PCI术后支架内再狭窄的影响因素分析[J].中国心血管病研究,2017,15(12):1098-1101. 吴天源,李韶南,罗义,等.CYP2C19中代谢型急性冠脉综合征患者PCI术后支架内再狭窄的影响因素分析[J].中国心血管病研究,2017,15(12):1098-1101.
9、 SCOTT S A,SANGKUHL K,SHULDINER A R,et al.TPharmGKB summary:very important pharmacogene information for cytochrome P450,family 2,subfamily C,polypeptide 19[J].Pharmacogenet Genomics,2012,22(2):159-165. SCOTT S A,SANGKUHL K,SHULDINER A R,et al.TPharmGKB summary:very important pharmacogene information for cytochrome P450,family 2,subfamily C,polypeptide 19[J].Pharmacogenet Genomics,2012,22(2):159-165.
10、 吴铮,李文铮,王长华,等.CYP2C19基因多态性与PCI术后氯吡格雷治疗患者血小板功能、炎性指标及病情转归的相关性[J].疑难病杂志,2019,18(8):770-774. 吴铮,李文铮,王长华,等.CYP2C19基因多态性与PCI术后氯吡格雷治疗患者血小板功能、炎性指标及病情转归的相关性[J].疑难病杂志,2019,18(8):770-774.
11、 NADER S,KAMRAN M,AMIN H,et al.The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis[J].Genes Environ,2021,43(1):1. NADER S,KAMRAN M,AMIN H,et al.The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis[J].Genes Environ,2021,43(1):1.
12、 GAO Y,LOU Y,LIU Y,et al.The relationship between residual cholesterol risk and plaque characteristics in patients with acute coronary syndrome: Insights from an optical coherence tomography study[J].Atherosclerosis,2021,3(17):10-15. GAO Y,LOU Y,LIU Y,et al.The relationship between residual cholesterol risk and plaque characteristics in patients with acute coronary syndrome: Insights from an optical coherence tomography study[J].Atherosclerosis,2021,3(17):10-15.
13、 CHA J J,LIM D S.Precision antiplatelet therapy for CYP2C19 genotype variants for achieving better clinical outcomes[J].JACC Cardiovasc Interv,2021,14(13):1500-1501. CHA J J,LIM D S.Precision antiplatelet therapy for CYP2C19 genotype variants for achieving better clinical outcomes[J].JACC Cardiovasc Interv,2021,14(13):1500-1501.
14、 RENAN S,ERICK H,SISKA S,et al.Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)[J].Pharmacol Res Perspect,2021,9(2):1-8. RENAN S,ERICK H,SISKA S,et al.Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)[J].Pharmacol Res Perspect,2021,9(2):1-8.
